Christoph Wiessner is the Chief Operating Officer, and a Founder of Asceneuron SA.  He has more than 20 years of experience in neuroscience and drug discovery with a focus on developing novel therapies for neurodegenerative diseases including stroke, spinal cord injury, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Orphan Tauopathies. Prior to Asceneuron, he was a director at Merck Serono, Geneva, Switzerland (2008-2012) in the Therapeutic Area “Neurodegenerative Diseases”. From 1996-2008 he worked with increasing responsibilities in the CNS department at Novartis in Basel, Switzerland, and finally headed the CNS Target and Lead Discovery Unit as a director. At Novartis he also led the drug discovery team for CAD106, a vaccine for Alzheimer’s Disease currently in Phase II/III, and contributed to several CNS projects that entered into clinical testing. Christoph obtained his PhD in the department of Nobel laureate Hartmut Michel at the Max-Planck-Institute for Biophysics, Frankfurt, Germany. Subsequently he joined the department of Konstantin-Alexander Hossmann at the Max-Planck-Institute for Neurological Research, Cologne, Germany, and concluded this work with a habilitation in Experimental Neurology at the Medical Faculty of the University of Cologne. He has authored > 60 peer-reviewed publications, reviews, and book chapters with over 4300 citations and an H-index of 35 according to Google Scholar.

  neuroscience and drug discovery with a focus on developing novel therapies for neurodegenerative diseases including stroke, spinal cord injury , Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Orphan Tauopathies